Ron Cohen, President and CEO, Acorda Therapeutics, Inc.

Type:

Video

Dr. Cohen discusses the plight of today’s emerging biotech companies, and how the federal government can best support innovation within the industry so that the U.S. remains globally competitive. Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with MS, spinal cord injury and other neurological conditions.

December 8, 2010 Intellectual Property in Emerging Markets	July 29, 2010 DOE’s Assistant Secretary Zoi Announces Funding of $24 million Research Groups	June 23, 2010 BioBytes: The Biotech Drug Delivery Timeline	June 15, 2010 BioBytes: Biotechnology and Diagnostic Tools
June 1, 2010 BioBytes: Marine Biotechnology	May 25, 2010 BioBytes: Biotechnology and Plant Made Pharmaceuticals	May 19, 2010 BioBytes: Forensics and Biotechnology	May 19, 2010 BioBytes: Forensics and Biotechnology